Genta R M
Department of Pathology, University of Geneva, Switzerland.
Aliment Pharmacol Ther. 2003 Jul;18 Suppl 1:8-13. doi: 10.1046/j.1365-2036.18.s1.5.x.
Rebamipide stimulates the generation of endogenous prostaglandins in the gastric mucosa and is reported to accelerate ulcer healing. This review discusses whether rebamipide can prevent Helicobacter pylori infection, reduce inflammation, accelerate healing after eradication, promote ulcer healing, and prevent progression of preneoplastic lesions. Furthermore, we evaluate its usefulness in other inflammatory conditions of the gastrointestinal tract. We conclude that rebamipide is an important candidate for long-term suppression of gastro-intestinal inflammation, particularly if reducing the complications of H. pylori infection without eradicating the organism becomes accepted. If its ability to accelerate mucosal normalization is confirmed, rebamipide could be added to eradication regimens. Little information exists on whether such therapy could help limit the development of pre-neoplastic lesions. In light of the dearth of effective drugs to control inflammation in idiopathic inflammatory bowel disease, the potential of any promising new and safe compound deserves to be fully explored. The next step is to devise a targeted plan of translational research, so that results from the bench may be used to design rigorously controlled international clinical trials.
瑞巴派特可刺激胃黏膜内源性前列腺素的生成，据报道能加速溃疡愈合。本综述探讨了瑞巴派特是否可预防幽门螺杆菌感染、减轻炎症、根除幽门螺杆菌后加速愈合、促进溃疡愈合以及预防癌前病变进展。此外，我们评估了其在胃肠道其他炎症性疾病中的效用。我们得出结论，瑞巴派特是长期抑制胃肠道炎症的重要候选药物，特别是如果在不根除幽门螺杆菌的情况下减少其感染并发症成为可接受的做法。如果其加速黏膜正常化的能力得到证实，瑞巴派特可添加到根除方案中。关于这种疗法是否有助于限制癌前病变的发展，目前信息很少。鉴于控制特发性炎症性肠病炎症的有效药物匮乏，任何有前景的新型安全化合物的潜力都值得充分探索。下一步是制定有针对性的转化研究计划，以便实验室研究结果可用于设计严格对照的国际临床试验。
